Niche healthcare stock Haemonetics (HAE +3.85%) was a winner among the clutch of publicly traded companies reporting quarterly earnings on Thursday. On the back of an estimates-beating second quarter of fiscal 2026, investors piled into its shares to push them in excess of 32% higher. That looked particularly impressive next to the bellwether S&P 500's (^GSPC 0.29%) 1.1% drop that trading session. On Friday, the rally continued, as the stock was up by over 3% that morning.
A tale of two fundamentals
Haemonetics, which concentrates on hematology products and services, booked revenue of $327 million for the quarter. Although that was 5% down year over year, it handily topped the average analyst expectation of under $312 million.
Image source: Getty Images.
Happily, the company's net income not according to generally accepted accounting principles (so, it was adjusted) veered in the other direction. It climbed more than 5% higher to slightly over $60 million, or $1.27 per share. This too bettered the pundit consensus, which was $1.11.
In its earnings release, Haemonetics quoted CEO Chris Simon as saying the results "demonstrate disciplined execution and increasingly profitable growth across our business."
NYSE: HAE
Key Data Points
Revenue guidance lifted
Compounding the twin beats, Haemonetics also adjusted its full-year fiscal 2026 revenue and earnings guidance. For the former, it now feels that the metric will see a decline of 1% to growth of 2% over the 2025 number; previously it was guiding for a drop of 2% to a rise of 1%.
Management also lifted the low end of non-GAAP (adjusted) net income, which should be $4.80 to $5.00 per share for the year. The average analyst estimate is $4.83. The former range was $4.70 to $5.00.
Haemonetics is an under-the-radar niche healthcare company that's getting some investor love with its impressive quarter. As a profitable and growing business, it's certainly worth a look for value investors.
